FDA Clearance Tracker · P100045-S056
CardioMEMs HF System
Last checked: Nov 20, 2026Latest source record: Feb 18, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Feb 18, 2022
Approved
Time to decision
232 days
Received Jul 1, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P100045-S056
- Device name
- CardioMEMs HF System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Atlanta, GA
- Received
- Jul 1, 2021
- Decided
- Feb 18, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P100045
Device type
- Device type
- System, hemodynamic, implantable (MOM)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the CardioMEMS HF System. The device is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.